Long-Term Antithyroid Drug Treatment: Trends in Serum TSH and TSH Receptor Antibody Changes in Patients with Graves’ Disease

Objectives: Trends in serum thyroid-stimulating hormone (TSH) and TSH receptor antibody (TRAb) changes during antithyroid drug treatment, and long-term prognosis were evaluated in Graves’ hyperthyroidism (GD). Methods: In 609 GD patients initially treated with 15 mg of methyl-mercapto imidazole (MMI), the changes in serum TRAb and long-term prognosis were compared in the TSH-normalized group (A) and the TSH-suppressed group (B and C) during the initial 180 days of treatment. Results: Early responses to MMI during 180 days of treatment were as follows: 48 cases (7.9%) became hypothyroid with elevated TSH (A1), and 188 cases (30.9%) became euthyroid with normal TSH (A2). Among patients with continuously suppressed TSH, the free T4 (fT4) level was low in 31 cases (5.1%) (B1-inappropriately suppressed TSH), fT4 and fT3 were normal in 185 cases (30.4%) (B2), fT4 was normal, but fT3 remained high in 84 cases (13.8%) (B3), and fT4 remained high in 73 cases (12.0%) (C-refractory). Serum TRAb became negative after < 5 years then remained negative in 25% - 51% of the cases (smooth type), became negative after < 5 years then became positive again in 30% - 43% of the cases (fluctuating type), and remained positive after > 5 years in 10% - 42% of the cases (smoldering type). In total, remission occurred after 6.2 (3.0 - 10.4) years of treatment in 42%, possible remission on a small maintenance dosage of antithyroid drug occurred in 13%, and spontaneous hypothyroidism occurred in 4.4% of the cases. The smoldering type was more frequent in the B1 and C groups than in others, and remission was less frequent. The difference in the long-term prognosis depending on the early response to MMI disappeared after excluding the ablated patients. Without ablation, remission or spontaneous hypothyroidism could be expected in 60% - 75% of patients after tenacious treatment for > 10 years. Conclusions: Prolonged suppression of serum TSH may suggest active TRAb activity during treatment, and continuous TRAb positivity for more than 5 years suggests persistent GD activity.

[1]  F. Azizi,et al.  Increased remission rates after long-term methimazole therapy in patients with Graves' disease: Results of a randomized clinical trial. , 2019, Thyroid : official journal of the American Thyroid Association.

[2]  H. Ikenoue,et al.  The long-term follow-up of patients with thionamide-treated Graves' hyperthyroidism. , 2019, Endocrine journal.

[3]  S. Pearce,et al.  2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism , 2018, European Thyroid Journal.

[4]  Фадеев Валентин Викторович,et al.  Review of American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. , 2017 .

[5]  S. Rivkees,et al.  2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. , 2016, Thyroid : official journal of the American Thyroid Association.

[6]  ItoKoichi,et al.  Antithyroid drug treatment for graves' disease in children: a long-term retrospective study at a single institution. , 2014 .

[7]  T. Santos,et al.  Thyroglobulin in the Washout Fluid of Lymph-Node Biopsy: What Is Its Role in the Follow-Up of Differentiated Thyroid Carcinoma? , 2014 .

[8]  Kunihiko Ito,et al.  Antithyroid drug treatment for graves' disease in children: a long-term retrospective study at a single institution. , 2014, Thyroid : official journal of the American Thyroid Association.

[9]  M. Benmerad,et al.  Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study. , 2012, The Journal of clinical endocrinology and metabolism.

[10]  C. Gordon,et al.  Approach to the adolescent requesting contraception. , 2012, The Journal of clinical endocrinology and metabolism.

[11]  J. Jung,et al.  Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients. , 2006, Thyroid : official journal of the American Thyroid Association.

[12]  F. Azizi,et al.  Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. , 2005, European journal of endocrinology.

[13]  M. Prummel,et al.  Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients. , 2003, The Journal of clinical endocrinology and metabolism.

[14]  N. Takasu,et al.  Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment. , 2000, Thyroid : official journal of the American Thyroid Association.

[15]  C. Massart,et al.  Antithyroid drugs and Graves' disease — prospective randomized assessment of long‐term treatment , 1999, Clinical endocrinology.

[16]  J. Taft,et al.  The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. , 1998, Thyroid : official journal of the American Thyroid Association.

[17]  P. Carayon,et al.  Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. , 1994, The Journal of clinical endocrinology and metabolism.

[18]  Hong-Kyu Lee,et al.  Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease , 1992, Clinical endocrinology.

[19]  M. Fujishima,et al.  Prediction of relapse in drug-treated Graves' disease using thyroid stimulation indices. , 1991, Acta endocrinologica.

[20]  R. Fauchet,et al.  Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. , 1990, The Journal of clinical endocrinology and metabolism.

[21]  R. Holle,et al.  Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. , 1989, Acta endocrinologica.

[22]  M. Fujishima,et al.  Reevaluation of the thyroidal radioactive iodine uptake test, with special reference to reversible primary hypothyroidism with elevated thyroid radioiodine uptake. , 1988, The Journal of clinical endocrinology and metabolism.

[23]  R. Gregg,et al.  Binding of thyroid hormones to human plasma lipoproteins. , 1988, The Journal of clinical endocrinology and metabolism.

[24]  M. Fujishima,et al.  Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism. , 1987, The Journal of clinical endocrinology and metabolism.

[25]  E. Landaw,et al.  Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. , 1987, The Journal of clinical endocrinology and metabolism.

[26]  M. Fujishima,et al.  Treatment of hyperthyroidism with a small single daily dose of methimazole. , 1986, The Journal of clinical endocrinology and metabolism.

[27]  F. Karlsson,et al.  Thyrotropin-releasing hormone testing during antithyroid drug treatment of Graves' disease as an indicator of remission. , 1985, The Journal of clinical endocrinology and metabolism.

[28]  G. Beckett,et al.  A sensitive immunoradiometric assay for serum thyroid stimulating hormone: a replacement for the thyrotrophin releasing hormone test? , 1984, British medical journal.

[29]  C. Teng,et al.  Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study. , 1980, The Journal of clinical endocrinology and metabolism.

[30]  B. A. Burrows,et al.  Long-term antithyroid treatment in hyperthyroidism. , 1979, JAMA.

[31]  P. Marsden,et al.  EARLY DETECTION OF RELAPSE IN HYPERTHYROIDISM , 1975, The Lancet.

[32]  J. Staub,et al.  EARLY DETECTION OF RELAPSE IN HYPERTHYROIDISM BY T.R.H. TEST , 1975, The Lancet.

[33]  F. Azizi,et al.  Recovery of pituitary thyrotropic function after withdrawal of prolonged thyroid-suppression therapy. , 1975, The New England journal of medicine.

[34]  B. Smith,et al.  THYROID-STIMULATING IMMUNOGLOBULINS IN GRAVES' DISEASE , 1974 .

[35]  L. Wartofsky.  Low remission after therapy for Graves disease. Possible relation of dietary iodine with antithyroid therapy results. , 1973, JAMA.

[36]  J. Hershman,et al.  Direct evaluation of pituitary thyrotopin reserve utilizing synthetic thyrotopin releasing hormone. , 1971, The Journal of clinical endocrinology and metabolism.

[37]  S. Werner,et al.  A new and simple test for hyperthyroidism employing L-triiodothyronine and the twenty-four hour I-131 uptake method. , 1955, Bulletin of the New York Academy of Medicine.